secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rallybio Corp (RLYB)
CIK:        0001739410
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001739410-24-000053
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rallybio posts Q1 net loss of $19.0M; cash $94.2M; on track for RLYB212 Phase 2 in 2H 2024
--------------------------------------------------------------------------------

- Net loss of $19.0M ($0.47 per share) vs $17.3M ($0.43 per share) in Q1 2023.
- Cash, cash equivalents, and marketable securities of $94.2M as of March 31, 2024; runway into mid-2026.
- Announced 45% workforce reduction in Feb 2024 to focus on RLYB212 and RLYB116.
- Collaboration with Johnson & Johnson (Momenta) for FNAIT; received $6.6M equity investment.
- Phase 2 trial of RLYB212 in pregnant women at risk for FNAIT on track for 2H 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739410/000173941024000053/0001739410-24-000053-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739410/000173941024000053/rlyb-20240509.htm
  HTML page:      https://secwatch.observer/filing/0001739410-24-000053

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer